Business Context and Reporting Period
A SPAC III Acquisition Corp. (ASPC) is a blank check company incorporated in the British Virgin Islands, formed to effect a business combination with one or more businesses, specifically targeting the Environmental, Sustainability, and Governance (ESG) and material technology sectors. This Form 10-Q covers the quarter and nine months ended September 30, 2025. The Company completed its Initial Public Offering (IPO) in November 2024 and has not yet commenced operations.
Key Financial Metrics
| Metric | As of/For Period Ended Sept 30, 2025 | As of/For Period Ended Dec 31, 2024 |
|---|---|---|
| Cash and Cash Equivalents | $1,062,632 | $1,598,890 |
| Investments Held in Trust Account | $62,268,671 | $60,356,959 |
| Total Assets | $63,360,882 | $62,075,158 |
| Working Capital | $562,646 | $1,200,865 |
| Net Income (9 Months) | $1,273,493 | $(46,778) (Loss) |
| Interest Income (9 Months) | $1,948,362 | $0 |
| General & Administrative Expenses (9 Months) | $674,869 | $46,778 |
| Debt (Promissory Note) | $0 | $276,221 |
Material Changes vs. Prior Period
- Profitability: The Company reported a net income of $1,273,493 for the nine months ended September 30, 2025, compared to a net loss of $46,778 in the same period in 2024. This shift is primarily driven by significant interest income ($1,948,362) earned on the Trust Account following the November 2024 IPO.
- Operating Expenses: General and administrative expenses increased substantially to $674,869 for the nine months ended September 30, 2025, from $46,778 in the prior year, reflecting the costs of operating as a public company and pursuing a business combination.
- Liquidity: Cash held outside the Trust Account decreased from $1,598,890 to $1,062,632. The Company repaid its $276,221 promissory note to the related party in January 2025.
- Trust Account Growth: Investments in the Trust Account grew from $60.36 million to $62.27 million due to accrued interest.
Outlook, Management Commentary, and Risks
- Proposed Business Combination: On May 23, 2025, the Company entered into a Merger Agreement to acquire Bioserica International Limited, a developer of bio-based antimicrobial materials. The aggregate consideration is approximately $217.86 million, payable in newly issued shares.
- Extension and Redemptions: On October 27, 2025 (subsequent to the period end), shareholders approved an extension of the deadline to consummate a business combination to November 12, 2026. In connection with this vote, 5,717,419 Class A shares were redeemed for approximately $59.5 million, leaving approximately $2.9 million in the Trust Account.
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern if a business combination is not completed within the Combination Period. The financial statements do not include adjustments that might result from this uncertainty.
- Risks: Risks include the failure to consummate the proposed merger, market volatility, and the potential need for additional financing to complete the transaction or cover working capital deficiencies.
Key Facts for Investor Verification
- Post-Redemption Trust Balance: Verify the current Trust Account balance following the October 2025 redemptions, which reduced the account to approximately $2.9 million, significantly impacting the per-share redemption value.
- Merger Agreement Conditions: Confirm the status of conditions precedent required to close the Bioserica acquisition, including regulatory approvals and shareholder votes.
- Shareholder Ownership: Note that following the redemptions, the Sponsor holds approximately 76.4% of the outstanding ordinary shares.
- Extension Deadline: The Company now has until November 12, 2026, to complete a business combination or liquidate.
- Working Capital: Assess the sufficiency of the $1.06 million cash on hand to fund operations and transaction costs until the merger closes or liquidation occurs.